ClinicalTrials.gg
Active, not recruitingNCT06446765MIND-BPDUpdated Oct 19, 2026

Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder

A Phase 2 interventional study of mindfulness-based Neurofeedback and control Neurofeedback in Borderline Personality Disorder, sponsored by Yale University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Yale University · Phase 2, Interventional, and Treatment

How we know

Updated Oct 19, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Borderline Personality Disorder with a site in United States — 15 open to participants now, 17 under way, none of them phase 3. Borderline Personality Disorder · United States.

Enrollment
37th of 71
46 · median 56
Started
2025
with 3 others
Phase 2
16 of 81
1 open now
Primary completion
2026-07
later than 5 of 16 live
Registered
73rd of 81
by date
Lead sponsor
5 of 81
Yale University

Among the 81 studies in Borderline Personality Disorder with a site in United States, this one is the 37th largest by enrollment of the 71 interventional ones that give a count, is one of 4 that started in 2025, is one of 16 in phase 2, reaches primary completion later than 5 of the 16 other live ones, and was the 73rd registered.

Borderline Personality Disorder

279 studies on the registry are indexed under Borderline Personality Disorder; 70 are open to participants now.

Browse Borderline Personality Disorder studies →

Open to participants now

15 of the 81 studies in Borderline Personality Disorder with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Borderline Personality Disorder studies recruiting now, 18 (37%) set no upper age limit and 30 (61%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Borderline Personality Disorder with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to test the ability of mindfulness-based real time functional magnetic resonance imaging (fMRI) neurofeedback (mbNF) to increase the benefits of evidence-based psychotherapy for adults with Borderline Personality Disorder (BPD).

Read the detailed description

The focus of this study is Aim 1.

03

Conditions studied

  • Borderline Personality Disorder

Keywords

  • fMRI neurofeedback
  • mindfulness
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age 18-60,
  • be able to provide written ,
  • meet criteria for BPD on semi-structured clinical interview,
  • able to plan to keep any prescribed medications and psychotherapy constant during the study
  • fluent in English.

Exclusion criteria

Exclusion criteria:

  • current DBT psychotherapy outside the study
  • lifetime primary psychotic disorder
  • manic episode in the last one year
  • developmental disorder (e.g. autism)
  • history of learning disorder
  • severe substance use disorder in the last 3 months
  • active suicidal ideation with intent or plan in the past 3 months
  • history of major medical or neurologic disorder
  • MRI , including pregnancy
  • poor performance on reading task (WRAT > 11 errors)
  • newly prescribed medications in the past 8 weeks
  • daytime sedating medications (e.g. benzodiazepines, opiates, sedating neuroleptics)
  • any scheduled daily benzodiazepines
  • change in psychotherapy type or frequency in the past 12 weeks.
  • At the discretion of the study PI

Eligibility will be determined by study personnel.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    mindfulness-based Neurofeedback

    Participants will participate in one session of mindfulness-based fMRI neurofeedback followed by 20 weeks of remote online weekly Dialectical Behavior Therapy skills group.

    Behavioral: mindfulness-based Neurofeedback

  • Other
    control Neurofeedback

    Participants will participate in one session of control fMRI neurofeedback followed by 20 weeks of remote online weekly Dialectical Behavior Therapy skills group.

    Other: control Neurofeedback

Interventions

  • Behavioralmindfulness-based Neurofeedback

    Participants will complete one session of mindfulness-based fMRI neurofeedback prior to 20 weeks of remote online weekly DBT skills group.

  • Othercontrol Neurofeedback

    Participants will complete one session of control fMRI neurofeedback prior to 20 weeks of remote online weekly DBT skills group.

06

What researchers measure

Primary outcomes

  1. Change in within-Default Mode Network (DMN) resting state functional connectivity after one session of neurofeedback (NF)

    Defined as within-DMN connectivity as the resting state seed-based connectivity between core nodes of medial prefrontal cortex (mPFC) and posterior cingulate cortex (PCC). Change = post-NF within-DMN connectivity - pre-NF within-DMN connectivity.

    Time frame: From baseline (immediately before neurofeedback) to immediately after neurofeedback on the same day

  2. Change in DMN-Frontoparietal Control Network (FPCN) anticorrelation in resting state functional connectivity data after one session of neurofeedback

    Defined as DMN-FPCN anticorrelation as the fMRI seed-based connectivity from mPFC to dorsolateral prefrontal cortex (dlPFC)). Change = post-NF mPFC-dlPFC anticorrelation - pre-NF mPFC-dlPFC anticorrelation

    Time frame: From baseline (immediately before neurofeedback) to immediately after neurofeedback on the same day

Secondary outcomes

  1. Change from baseline in state mindfulness on State Mindfulness Scale (SMS) score on same day after neurofeedback.

    The State Mindfulness Scale (SMS) is a validated self-reported 21 item instrument assessing state mindfulness over the past 15 minutes. Possible scores range from 21 (not mindful) to 105 (very mindful).

    Time frame: From baseline (immediately before neurofeedback) to immediately after neurofeedback on the same day

07

Study locations

1 site
08

References and documents

Publications

  • Jones KG, Vandewouw MM, Awasthi J, Alario AA, Bauer C, Brewer B, Campbell NA, Denning D, Greene KD, Hammoud J, Hinds O, Huffman S, Maerker C, Paprotna S, Qiu M, Swinchoski B, Taylor A, Waite E, Wighton P, Whaley M, Papa J, Dixon-Gordon K, Hampson M, Whitfield-Gabrieli S, Fineberg SK. A protocol for MIndfulness-based Neurofeedback to augment DBT psychotherapy for adults with Borderline Personality Disorder (MIND-BPD). PLoS One. 2026 Mar 20;21(3):e0338002. doi: 10.1371/journal.pone.0338002. eCollection 2026. PubMed 41860884 ↗
  • Jones KG, Vandewouw MM, Awasthi J, Alario AA, Bauer C, Brewer B, Campbell N, Denning D, Greene KD, Hammoud J, Hinds O, Huffman S, Maerker C, Paprotna S, Qiu M, Swinchoski B, Taylor A, Waite E, Wighton P, Whaley M, Papa J, Gordon KD, Hampson M, Whitfield-Gabrieli S, Fineberg SK. A protocol for MIndfulness-based Neurofeedback to augment DBT psychotherapy for adults with Borderline Personality Disorder (MIND-BPD). medRxiv [Preprint]. 2025 Nov 19:2025.11.18.25340531. doi: 10.1101/2025.11.18.25340531. PubMed 41332880 ↗

Individual participant data

Plan to share: Yes — Sharing will occur as required by NIMH through the National Data Archive.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2025 to primary completion in Jul 2026, 16 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Oct 2026 → Jul 2026 and completion Oct 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2024
First posted
Jun 6, 2024
StartActual
Mar 13, 2025
Primary completionActual
Jul 14, 2026was Oct 2026
CompletionEst.
Mar 30, 2027was Oct 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 19, 2026
Primary completion
Oct 30, 2026→Jul 14, 2026 (actual)
Oct 19, 2026
Study completion
Oct 30, 2026→Mar 30, 2027
Oct 19, 2026
Enrollment
150 (estimated)→46 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Recruiting→Active, not recruiting
    Primary completion Oct 30, 2026→Jul 14, 2026 (now actual)
    Study completion Oct 30, 2026→Mar 30, 2027
    Enrollment 150 (estimated)→46 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06446765
Lead sponsor
Yale University
Collaborators
Connecticut Mental Health Center, National Institute of Mental Health (NIMH)
Responsible party
Sponsor
First posted
Jun 6, 2024
Start date
Mar 13, 2025
Primary completion
Jul 14, 2026
Completion
Mar 30, 2027 (estimated)
Last update
Oct 19, 2026

Study contacts

Sarah K Fineberg, MD PhD
principal investigator · Yale University

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion